Mineralys Therapeutics Inc.
- Address
- 150 North Radnor Chester Road Suite F200
Sponsor Overview
Specializations
Hypertension Research
Mineralys Therapeutics Inc. focuses on clinical research in hypertension, with an emphasis on blood pressure control and sustained antihypertensive effect in people requiring ongoing treatment.
- Blood pressure reduction
- Long-term antihypertensive maintenance
- Treatment response in hypertension
The sponsor’s research activity includes studies centered on improving systolic blood pressure outcomes and evaluating treatment durability in adults with elevated blood pressure.
Uncontrolled and Resistant Hypertension
The sponsor also investigates uncontrolled hypertension and resistant hypertension, addressing patients whose blood pressure remains difficult to manage with prescribed therapy.
- Resistant blood pressure management
- Adjunctive antihypertensive therapy
- Persistent hypertension control
These trials examine therapeutic strategies for individuals with inadequate blood pressure control despite existing antihypertensive treatment.
Mineralocorticoid Receptor Antagonism
Mineralys Therapeutics Inc. is engaged in research involving mineralocorticoid receptor-targeted therapy, with clinical interest in its role in blood pressure regulation and cardiovascular risk reduction.
- Mineralocorticoid receptor modulation
- Cardiovascular blood pressure control
- Therapy for difficult-to-treat hypertension
This area of interest extends to treatment approaches aimed at improving outcomes in patients with hypertensive disease requiring additional therapeutic options.
Renal and Albuminuria-Related Outcomes
The sponsor’s clinical program includes attention to albuminuria as a relevant outcome in hypertension research, reflecting interest in kidney-related effects associated with elevated blood pressure.
- Albuminuria improvement
- Kidney-related hypertension outcomes
- Blood pressure and renal markers
These studies connect renal health considerations with the management of chronic hypertension.
Long-Term Safety and Tolerability
Clinical research activity also covers the safety and tolerability profile of hypertension treatments, with continued assessment of sustained use in chronic care settings.
- Long-term treatment safety
- Tolerability in chronic hypertension
- Ongoing therapeutic monitoring
This work supports evaluation of treatment use over time in patients with persistent cardiovascular disease risk.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Long-Term Safety, Efficacy, and Tolerability Assessment of Lorundrostat in Hypertension: An Open-Label Extension Study |  Bulgaria France Germany Italy Poland Romania Spain The Netherlands | Not Recruiting |
| Phase 3 Multicenter Study on Lorundrostat Efficacy and Safety in Uncontrolled and Resistant Hypertension | Bulgaria France Germany Italy Poland Romania Spain The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 72 sites across their trial portfolio.
Therapeutic Focus
- 1.Cardiovascular Diseases2 trials359 other sponsors
Partnered Research Centres
72 centres- Address
- Via Consolare Valeria N 1, 98124 Messina
- Address
- Albert Schweitzerplaats 25, 3318 AT Dordrecht
- Address
- Meibergdreef 9, 1105 AZ Amsterdam
- Address
- De Boelelaan 1117, 1081 HV Amsterdam
- Address
- Strada Republicii Nr 8, 400015 Cluj Napoca
- Address
- Avenida Residencia S/n, 15405 Ferrol
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Mineralys Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.